REGENERON PHARMACEUTICALS, INC. Revenue From Contract With Customer Excluding Assessed Tax

Quick Answer

REGENERON PHARMACEUTICALS, INC. reported Revenue From Contract With Customer Excluding Assessed Tax of $14.34 billion for the year ending 2025.

  • REGENERON PHARMACEUTICALS, INC. showed an increase of +1.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
  • This data is from REGENERON PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 4, 2026.
  • XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 10 years of available data (2016 to 2025), REGENERON PHARMACEUTICALS, INC.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 195.1%.
  • Historical annual values: Fiscal year 2025: $14.34 billion | Fiscal year 2024: $14.20 billion | Fiscal year 2023: $13.12 billion | Fiscal year 2022: $12.17 billion | Fiscal year 2021: $16.07 billion | Fiscal year 2020: $8.50 billion | Fiscal year 2019: $6.56 billion | Fiscal year 2018: $5.15 billion | Fiscal year 2017: $5.87 billion | Fiscal year 2016: $4.86 billion.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: